[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fy5RJrJJECJ1sL2FJ32zcziafzCv7a_caUDMSjidsnek":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":33,"phaseBuckets":34,"rows":41},"University at Buffalo",[4],76,false,1,9,12679,0,41,[14,17,20,22,25,27,29,31],{"name":15,"count":16},"Multiple Sclerosis",14,{"name":18,"count":19},"Type 1 Diabetes",6,{"name":21,"count":19},"Type 2 Diabetes",{"name":23,"count":24},"Food Habits",2,{"name":26,"count":24},"Obesity",{"name":28,"count":24},"Insulin Resistance",{"name":30,"count":24},"Healthy",{"name":32,"count":24},"Control",[],[35,36,37,38,39,40],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[42,69,97,123,149,167,194,212,241,259,277,295,320,345,363,388,414,432,457,486,512,537,561,579,645,683,722,744,780,809,827,851,869,894,912,930,953,978,996,1019,1044,1068],{"intervention":43,"totalTrials":8,"cells":44},"Exenatide Extended Release for Inj Susp 2 MG",{"EARLY_PHASE1":45,"PHASE1":47,"PHASE2":49,"PHASE3":51,"PHASE4":53,"NA":67},{"trials":46,"activeCount":11},[],{"trials":48,"activeCount":11},[],{"trials":50,"activeCount":11},[],{"trials":52,"activeCount":11},[],{"trials":54,"activeCount":11},[55],{"nctId":56,"briefTitle":57,"status":58,"phases":59,"primaryCompletion":60,"completion":60,"start":61,"enrollment":62,"conditions":63,"interventions":66},"NCT03029351","GLP-1 Receptor Agonist Therapy and Albuminuria in Patients With Type 2 Diabetes","TERMINATED",[39],"2019-07","2017-01-10",15,[64,65],"Type2 Diabetes","Kidney Diseases",[43],{"trials":68,"activeCount":11},[],{"intervention":70,"totalTrials":8,"cells":71},"androgel 10g",{"EARLY_PHASE1":72,"PHASE1":74,"PHASE2":76,"PHASE3":78,"PHASE4":80,"NA":95},{"trials":73,"activeCount":11},[],{"trials":75,"activeCount":11},[],{"trials":77,"activeCount":11},[],{"trials":79,"activeCount":11},[],{"trials":81,"activeCount":11},[82],{"nctId":83,"briefTitle":84,"status":85,"phases":86,"primaryCompletion":87,"completion":88,"start":89,"enrollment":90,"conditions":91,"interventions":93},"NCT00350701","Effect of Androgel on Type 2 Diabetic Males With Hypogonadism","COMPLETED",[39],"2013-06","2013-07","2006-07",49,[92],"Diabetes Mellitus Type 2",[94,70],"androgel",{"trials":96,"activeCount":11},[],{"intervention":98,"totalTrials":8,"cells":99},"testosterone",{"EARLY_PHASE1":100,"PHASE1":102,"PHASE2":104,"PHASE3":106,"PHASE4":108,"NA":121},{"trials":101,"activeCount":11},[],{"trials":103,"activeCount":11},[],{"trials":105,"activeCount":11},[],{"trials":107,"activeCount":11},[],{"trials":109,"activeCount":11},[110],{"nctId":111,"briefTitle":112,"status":85,"phases":113,"primaryCompletion":114,"completion":115,"start":116,"enrollment":117,"conditions":118,"interventions":120},"NCT01127659","Testosterone Replacement in Men With Diabetes and Obesity",[39],"2015-03","2015-11","2010-05",137,[119],"Hypogonadism",[98],{"trials":122,"activeCount":11},[],{"intervention":124,"totalTrials":8,"cells":125},"Carvedilol Controlled Release",{"EARLY_PHASE1":126,"PHASE1":128,"PHASE2":130,"PHASE3":132,"PHASE4":134,"NA":147},{"trials":127,"activeCount":11},[],{"trials":129,"activeCount":11},[],{"trials":131,"activeCount":11},[],{"trials":133,"activeCount":11},[],{"trials":135,"activeCount":11},[136],{"nctId":137,"briefTitle":138,"status":58,"phases":139,"primaryCompletion":140,"completion":140,"start":141,"enrollment":16,"conditions":142,"interventions":145},"NCT00430040","Vascular Benefits of Adding CarvedilolCR to Type2 Diabetic Patients on ACEI.",[39],"2013-05","2007-02",[143,144],"Diabetes Mellitus, Type 2","Hypertension",[124,146],"lisinopril",{"trials":148,"activeCount":11},[],{"intervention":146,"totalTrials":8,"cells":150},{"EARLY_PHASE1":151,"PHASE1":153,"PHASE2":155,"PHASE3":157,"PHASE4":159,"NA":165},{"trials":152,"activeCount":11},[],{"trials":154,"activeCount":11},[],{"trials":156,"activeCount":11},[],{"trials":158,"activeCount":11},[],{"trials":160,"activeCount":11},[161],{"nctId":137,"briefTitle":138,"status":58,"phases":162,"primaryCompletion":140,"completion":140,"start":141,"enrollment":16,"conditions":163,"interventions":164},[39],[143,144],[124,146],{"trials":166,"activeCount":11},[],{"intervention":168,"totalTrials":8,"cells":169},"Rapamune",{"EARLY_PHASE1":170,"PHASE1":172,"PHASE2":174,"PHASE3":176,"PHASE4":178,"NA":192},{"trials":171,"activeCount":11},[],{"trials":173,"activeCount":11},[],{"trials":175,"activeCount":11},[],{"trials":177,"activeCount":11},[],{"trials":179,"activeCount":11},[180],{"nctId":181,"briefTitle":182,"status":85,"phases":183,"primaryCompletion":184,"completion":185,"start":186,"enrollment":187,"conditions":188,"interventions":190},"NCT00896012","Kidney Biopsy Controlled Trial of Calcineurin Inhibitor Withdrawal",[39],"2011-11-11","2011-12","2008-01",58,[189],"Kidney Transplantation",[168,191],"Tacrolimus",{"trials":193,"activeCount":11},[],{"intervention":191,"totalTrials":8,"cells":195},{"EARLY_PHASE1":196,"PHASE1":198,"PHASE2":200,"PHASE3":202,"PHASE4":204,"NA":210},{"trials":197,"activeCount":11},[],{"trials":199,"activeCount":11},[],{"trials":201,"activeCount":11},[],{"trials":203,"activeCount":11},[],{"trials":205,"activeCount":11},[206],{"nctId":181,"briefTitle":182,"status":85,"phases":207,"primaryCompletion":184,"completion":185,"start":186,"enrollment":187,"conditions":208,"interventions":209},[39],[189],[168,191],{"trials":211,"activeCount":11},[],{"intervention":213,"totalTrials":8,"cells":214},"Normal Saline",{"EARLY_PHASE1":215,"PHASE1":217,"PHASE2":219,"PHASE3":221,"PHASE4":223,"NA":239},{"trials":216,"activeCount":11},[],{"trials":218,"activeCount":11},[],{"trials":220,"activeCount":11},[],{"trials":222,"activeCount":11},[],{"trials":224,"activeCount":11},[225],{"nctId":226,"briefTitle":227,"status":85,"phases":228,"primaryCompletion":229,"completion":229,"start":230,"enrollment":231,"conditions":232,"interventions":235},"NCT02980835","Optimal Timing of Intercostal Nerve Blocks During Video-Assisted Thoracic Surgeries",[39],"2022-03-30","2016-09-28",36,[233,234],"Video-Assisted Thoracic Surgery","Video-Assisted Thoracoscopic Surgery",[213,236,237,238],"Ropivacaine","Epinephrine","Dexamethasone",{"trials":240,"activeCount":11},[],{"intervention":236,"totalTrials":8,"cells":242},{"EARLY_PHASE1":243,"PHASE1":245,"PHASE2":247,"PHASE3":249,"PHASE4":251,"NA":257},{"trials":244,"activeCount":11},[],{"trials":246,"activeCount":11},[],{"trials":248,"activeCount":11},[],{"trials":250,"activeCount":11},[],{"trials":252,"activeCount":11},[253],{"nctId":226,"briefTitle":227,"status":85,"phases":254,"primaryCompletion":229,"completion":229,"start":230,"enrollment":231,"conditions":255,"interventions":256},[39],[233,234],[213,236,237,238],{"trials":258,"activeCount":11},[],{"intervention":237,"totalTrials":8,"cells":260},{"EARLY_PHASE1":261,"PHASE1":263,"PHASE2":265,"PHASE3":267,"PHASE4":269,"NA":275},{"trials":262,"activeCount":11},[],{"trials":264,"activeCount":11},[],{"trials":266,"activeCount":11},[],{"trials":268,"activeCount":11},[],{"trials":270,"activeCount":11},[271],{"nctId":226,"briefTitle":227,"status":85,"phases":272,"primaryCompletion":229,"completion":229,"start":230,"enrollment":231,"conditions":273,"interventions":274},[39],[233,234],[213,236,237,238],{"trials":276,"activeCount":11},[],{"intervention":238,"totalTrials":8,"cells":278},{"EARLY_PHASE1":279,"PHASE1":281,"PHASE2":283,"PHASE3":285,"PHASE4":287,"NA":293},{"trials":280,"activeCount":11},[],{"trials":282,"activeCount":11},[],{"trials":284,"activeCount":11},[],{"trials":286,"activeCount":11},[],{"trials":288,"activeCount":11},[289],{"nctId":226,"briefTitle":227,"status":85,"phases":290,"primaryCompletion":229,"completion":229,"start":230,"enrollment":231,"conditions":291,"interventions":292},[39],[233,234],[213,236,237,238],{"trials":294,"activeCount":11},[],{"intervention":296,"totalTrials":8,"cells":297},"Linagliptin",{"EARLY_PHASE1":298,"PHASE1":300,"PHASE2":302,"PHASE3":304,"PHASE4":306,"NA":318},{"trials":299,"activeCount":11},[],{"trials":301,"activeCount":11},[],{"trials":303,"activeCount":11},[],{"trials":305,"activeCount":11},[],{"trials":307,"activeCount":11},[308],{"nctId":309,"briefTitle":310,"status":85,"phases":311,"primaryCompletion":312,"completion":313,"start":314,"enrollment":315,"conditions":316,"interventions":317},"NCT02372630","The Effect of LINAGLIPTIN on Inflammation, Oxidative Stress and Insulin Resistance in Obese Type 2 Diabetes Subjects",[39],"2018-02-01","2018-05-01","2014-05-23",40,[21],[296],{"trials":319,"activeCount":11},[],{"intervention":321,"totalTrials":8,"cells":322},"Pioglitazone 15mg",{"EARLY_PHASE1":323,"PHASE1":325,"PHASE2":327,"PHASE3":329,"PHASE4":331,"NA":343},{"trials":324,"activeCount":11},[],{"trials":326,"activeCount":11},[],{"trials":328,"activeCount":11},[],{"trials":330,"activeCount":11},[],{"trials":332,"activeCount":11},[333],{"nctId":334,"briefTitle":335,"status":85,"phases":336,"completion":337,"enrollment":338,"conditions":339,"interventions":341},"NCT01161394","Effect of Pioglitazone on Oxidative Load, Inflammatory End-Points and Vascular Reactivity in Obese Non-Diabetic Patients: A Dose Ranging Study",[39],"2003-10",24,[340],"Inflammation",[321,342],"pioglitazone 30mg",{"trials":344,"activeCount":11},[],{"intervention":342,"totalTrials":8,"cells":346},{"EARLY_PHASE1":347,"PHASE1":349,"PHASE2":351,"PHASE3":353,"PHASE4":355,"NA":361},{"trials":348,"activeCount":11},[],{"trials":350,"activeCount":11},[],{"trials":352,"activeCount":11},[],{"trials":354,"activeCount":11},[],{"trials":356,"activeCount":11},[357],{"nctId":334,"briefTitle":335,"status":85,"phases":358,"completion":337,"enrollment":338,"conditions":359,"interventions":360},[39],[340],[321,342],{"trials":362,"activeCount":11},[],{"intervention":364,"totalTrials":8,"cells":365},"Dexamethasone Sodium Phosphate",{"EARLY_PHASE1":366,"PHASE1":368,"PHASE2":370,"PHASE3":372,"PHASE4":384,"NA":386},{"trials":367,"activeCount":11},[],{"trials":369,"activeCount":11},[],{"trials":371,"activeCount":11},[],{"trials":373,"activeCount":11},[374],{"nctId":375,"briefTitle":376,"status":85,"phases":377,"primaryCompletion":378,"completion":378,"start":379,"enrollment":380,"conditions":381,"interventions":383},"NCT02192827","Use of Dexamethasone in Pediatric Asthma Exacerbations",[38],"2018-03","2015-04",318,[382],"Asthma",[364],{"trials":385,"activeCount":11},[],{"trials":387,"activeCount":11},[],{"intervention":389,"totalTrials":8,"cells":390},"Riboflavin-5-phosphate",{"EARLY_PHASE1":391,"PHASE1":393,"PHASE2":395,"PHASE3":397,"PHASE4":410,"NA":412},{"trials":392,"activeCount":11},[],{"trials":394,"activeCount":11},[],{"trials":396,"activeCount":11},[],{"trials":398,"activeCount":11},[399],{"nctId":400,"briefTitle":401,"status":402,"phases":403,"primaryCompletion":185,"completion":185,"start":404,"enrollment":405,"conditions":406,"interventions":408},"NCT00841386","Treatment of Keratoconus Using Collagen Cross-Linking","UNKNOWN",[37,38],"2008-09",150,[407],"Keratoconus",[389,409],"Sham cross-linking",{"trials":411,"activeCount":11},[],{"trials":413,"activeCount":11},[],{"intervention":409,"totalTrials":8,"cells":415},{"EARLY_PHASE1":416,"PHASE1":418,"PHASE2":420,"PHASE3":422,"PHASE4":428,"NA":430},{"trials":417,"activeCount":11},[],{"trials":419,"activeCount":11},[],{"trials":421,"activeCount":11},[],{"trials":423,"activeCount":11},[424],{"nctId":400,"briefTitle":401,"status":402,"phases":425,"primaryCompletion":185,"completion":185,"start":404,"enrollment":405,"conditions":426,"interventions":427},[37,38],[407],[389,409],{"trials":429,"activeCount":11},[],{"trials":431,"activeCount":11},[],{"intervention":433,"totalTrials":8,"cells":434},"Liraglutide 1.8mg",{"EARLY_PHASE1":435,"PHASE1":437,"PHASE2":439,"PHASE3":441,"PHASE4":453,"NA":455},{"trials":436,"activeCount":11},[],{"trials":438,"activeCount":11},[],{"trials":440,"activeCount":11},[],{"trials":442,"activeCount":11},[443],{"nctId":444,"briefTitle":445,"status":85,"phases":446,"primaryCompletion":447,"completion":448,"start":449,"enrollment":450,"conditions":451,"interventions":452},"NCT01722240","Liraglutide in Type 1 Diabetes",[38],"2019-01-01","2019-07-29","2012-11-01",69,[18],[433],{"trials":454,"activeCount":11},[],{"trials":456,"activeCount":11},[],{"intervention":458,"totalTrials":8,"cells":459},"Dapagliflozin placebo",{"EARLY_PHASE1":460,"PHASE1":462,"PHASE2":464,"PHASE3":466,"PHASE4":482,"NA":484},{"trials":461,"activeCount":11},[],{"trials":463,"activeCount":11},[],{"trials":465,"activeCount":11},[],{"trials":467,"activeCount":11},[468],{"nctId":469,"briefTitle":470,"status":85,"phases":471,"primaryCompletion":472,"completion":473,"start":474,"enrollment":475,"conditions":476,"interventions":478},"NCT02518945","Dapagliflozin As Additional Treatment To Liraglutide And Insulin In Patients With Type 1 Diabetes",[38],"2015-12","2016-04","2015-08",26,[477],"Type 1 Diabetes Mellitus",[479,480,481,458],"Dapagliflozin","Insulin","Liraglutide",{"trials":483,"activeCount":11},[],{"trials":485,"activeCount":11},[],{"intervention":487,"totalTrials":8,"cells":488},"repository corticotropin",{"EARLY_PHASE1":489,"PHASE1":491,"PHASE2":493,"PHASE3":506,"PHASE4":508,"NA":510},{"trials":490,"activeCount":11},[],{"trials":492,"activeCount":11},[],{"trials":494,"activeCount":11},[495],{"nctId":496,"briefTitle":497,"status":498,"phases":499,"primaryCompletion":500,"completion":501,"start":502,"enrollment":11,"conditions":503,"interventions":504},"NCT00986960","Effect of Adrenocorticotropin Injection With Weekly Interferon Beta in Patients With Relapsing Remitting Multiple Sclerosis (MS)","WITHDRAWN",[37],"2010-09","2010-12","2009-12",[15],[487,505],"Saline",{"trials":507,"activeCount":11},[],{"trials":509,"activeCount":11},[],{"trials":511,"activeCount":11},[],{"intervention":513,"totalTrials":8,"cells":514},"Minocycline",{"EARLY_PHASE1":515,"PHASE1":517,"PHASE2":519,"PHASE3":531,"PHASE4":533,"NA":535},{"trials":516,"activeCount":11},[],{"trials":518,"activeCount":11},[],{"trials":520,"activeCount":11},[521],{"nctId":522,"briefTitle":523,"status":498,"phases":524,"primaryCompletion":525,"completion":526,"start":527,"enrollment":11,"conditions":528,"interventions":530},"NCT02113176","Minocycline as Neuroprotectant After Aneurysmal Subarachnoid Hemorrhage",[36,37],"2016-12","2018-12","2010-01",[529],"Subarachnoid Aneurysm Hemorrhage",[513],{"trials":532,"activeCount":11},[],{"trials":534,"activeCount":11},[],{"trials":536,"activeCount":11},[],{"intervention":538,"totalTrials":8,"cells":539},"exenatide 5 mcg",{"EARLY_PHASE1":540,"PHASE1":542,"PHASE2":544,"PHASE3":555,"PHASE4":557,"NA":559},{"trials":541,"activeCount":11},[],{"trials":543,"activeCount":11},[],{"trials":545,"activeCount":11},[546],{"nctId":547,"briefTitle":548,"status":85,"phases":549,"primaryCompletion":550,"completion":550,"start":551,"enrollment":338,"conditions":552,"interventions":553},"NCT01154933","Exeantide in Type 2 Diabetes on Insulin",[37],"2011-11","2008-04",[21],[538,554],"exenatide 10 mcg",{"trials":556,"activeCount":11},[],{"trials":558,"activeCount":11},[],{"trials":560,"activeCount":11},[],{"intervention":554,"totalTrials":8,"cells":562},{"EARLY_PHASE1":563,"PHASE1":565,"PHASE2":567,"PHASE3":573,"PHASE4":575,"NA":577},{"trials":564,"activeCount":11},[],{"trials":566,"activeCount":11},[],{"trials":568,"activeCount":11},[569],{"nctId":547,"briefTitle":548,"status":85,"phases":570,"primaryCompletion":550,"completion":550,"start":551,"enrollment":338,"conditions":571,"interventions":572},[37],[21],[538,554],{"trials":574,"activeCount":11},[],{"trials":576,"activeCount":11},[],{"trials":578,"activeCount":11},[],{"intervention":481,"totalTrials":19,"cells":580},{"EARLY_PHASE1":581,"PHASE1":583,"PHASE2":585,"PHASE3":587,"PHASE4":632,"NA":634},{"trials":582,"activeCount":11},[],{"trials":584,"activeCount":11},[],{"trials":586,"activeCount":11},[],{"trials":588,"activeCount":11},[589,598,609,618,628],{"nctId":590,"briefTitle":591,"status":85,"phases":592,"primaryCompletion":593,"completion":594,"start":449,"enrollment":595,"conditions":596,"interventions":597},"NCT01722266","Liraglutide in the Treatment of Type 1 Diabetes Mellitus",[38],"2014-04-01","2014-12-01",72,[18],[481],{"nctId":599,"briefTitle":600,"status":85,"phases":601,"primaryCompletion":602,"completion":603,"start":604,"enrollment":605,"conditions":606,"interventions":607},"NCT01753362","Liraglutide In Overweight Patients With Type 1 Diabetes",[38],"2017-12","2018-02","2012-12",84,[18],[608],"liraglutide",{"nctId":610,"briefTitle":611,"status":498,"phases":612,"primaryCompletion":613,"completion":614,"start":615,"enrollment":11,"conditions":616,"interventions":617},"NCT01722227","Anti-diabetic Effects of Liraglutide in Adolescents and Young Subjects With Type 1 Diabetes",[38],"2017-11","2018-05","2012-11",[18],[481],{"nctId":619,"briefTitle":620,"status":85,"phases":621,"primaryCompletion":622,"completion":623,"start":624,"enrollment":625,"conditions":626,"interventions":627},"NCT02516657","Liraglutide in Adolescents With Type 1 Diabetes",[38],"2022-08-03","2023-08-03","2012-05",5,[18],[481],{"nctId":469,"briefTitle":470,"status":85,"phases":629,"primaryCompletion":472,"completion":473,"start":474,"enrollment":475,"conditions":630,"interventions":631},[38],[477],[479,480,481,458],{"trials":633,"activeCount":11},[],{"trials":635,"activeCount":11},[636],{"nctId":637,"briefTitle":638,"status":85,"phases":639,"primaryCompletion":640,"completion":87,"start":641,"enrollment":642,"conditions":643,"interventions":644},"NCT01299012","Liraglutide as Additional Treatment in Patients With Type 1 Diabetes Mellitus",[],"2013-02","2010-10",30,[477],[481],{"intervention":480,"totalTrials":646,"cells":647},3,{"EARLY_PHASE1":648,"PHASE1":650,"PHASE2":661,"PHASE3":663,"PHASE4":669,"NA":671},{"trials":649,"activeCount":11},[],{"trials":651,"activeCount":11},[652],{"nctId":653,"briefTitle":654,"status":85,"phases":655,"primaryCompletion":656,"completion":656,"start":657,"enrollment":642,"conditions":658,"interventions":660},"NCT02054429","Intensive Insulin Therapy With Tight Glycemic Control to Improve Outcomes After Endovascular Therapy for Acute Ischemic Stroke",[36],"2016-12-31","2013-01",[659],"Ischemic Stroke",[480],{"trials":662,"activeCount":11},[],{"trials":664,"activeCount":11},[665],{"nctId":469,"briefTitle":470,"status":85,"phases":666,"primaryCompletion":472,"completion":473,"start":474,"enrollment":475,"conditions":667,"interventions":668},[38],[477],[479,480,481,458],{"trials":670,"activeCount":11},[],{"trials":672,"activeCount":11},[673],{"nctId":674,"briefTitle":675,"status":85,"phases":676,"primaryCompletion":677,"completion":678,"start":404,"enrollment":642,"conditions":679,"interventions":680},"NCT01151605","The Suppression of Toll Like Receptors by Insulin",[40],"2013-09","2013-12",[28],[681,682,505],"insulin","Dextrose",{"intervention":479,"totalTrials":646,"cells":684},{"EARLY_PHASE1":685,"PHASE1":687,"PHASE2":689,"PHASE3":691,"PHASE4":697,"NA":708},{"trials":686,"activeCount":11},[],{"trials":688,"activeCount":11},[],{"trials":690,"activeCount":11},[],{"trials":692,"activeCount":11},[693],{"nctId":469,"briefTitle":470,"status":85,"phases":694,"primaryCompletion":472,"completion":473,"start":474,"enrollment":475,"conditions":695,"interventions":696},[38],[477],[479,480,481,458],{"trials":698,"activeCount":11},[699],{"nctId":700,"briefTitle":701,"status":85,"phases":702,"primaryCompletion":378,"completion":703,"start":115,"enrollment":704,"conditions":705,"interventions":706},"NCT02433678","An Investigation Into The Anti-hypertensive And Potential Anti-inflammatory Actions Of Dapagliflozin",[39],"2018-11",52,[21],[707],"dapagliflozin",{"trials":709,"activeCount":11},[710],{"nctId":711,"briefTitle":712,"status":85,"phases":713,"primaryCompletion":714,"completion":715,"start":716,"enrollment":717,"conditions":718,"interventions":720},"NCT02962492","An Investigation Into the Effect of Dapagliflozin on Ketogenesis in Type 1 Diabetes",[40],"2021-02-01","2021-10-24","2016-11-01",70,[719],"Evaluate Ketogenic Stress",[721,479],"Exenatide\u002FExenatide extended release",{"intervention":505,"totalTrials":24,"cells":723},{"EARLY_PHASE1":724,"PHASE1":726,"PHASE2":728,"PHASE3":734,"PHASE4":736,"NA":738},{"trials":725,"activeCount":11},[],{"trials":727,"activeCount":11},[],{"trials":729,"activeCount":11},[730],{"nctId":496,"briefTitle":497,"status":498,"phases":731,"primaryCompletion":500,"completion":501,"start":502,"enrollment":11,"conditions":732,"interventions":733},[37],[15],[487,505],{"trials":735,"activeCount":11},[],{"trials":737,"activeCount":11},[],{"trials":739,"activeCount":11},[740],{"nctId":674,"briefTitle":675,"status":85,"phases":741,"primaryCompletion":677,"completion":678,"start":404,"enrollment":642,"conditions":742,"interventions":743},[40],[28],[681,682,505],{"intervention":745,"totalTrials":24,"cells":746},"Dimethyl Fumarate",{"EARLY_PHASE1":747,"PHASE1":749,"PHASE2":751,"PHASE3":753,"PHASE4":755,"NA":757},{"trials":748,"activeCount":11},[],{"trials":750,"activeCount":11},[],{"trials":752,"activeCount":11},[],{"trials":754,"activeCount":11},[],{"trials":756,"activeCount":11},[],{"trials":758,"activeCount":11},[759,770],{"nctId":760,"briefTitle":761,"status":85,"phases":762,"primaryCompletion":763,"completion":763,"start":764,"enrollment":765,"conditions":766,"interventions":769},"NCT03526224","Teriflunomide Tecfidera LMCE",[],"2019-07-10","2018-06-14",120,[767,768],"Tecfidera","Teriflunomide",[745,768],{"nctId":771,"briefTitle":772,"status":85,"phases":773,"primaryCompletion":774,"completion":774,"start":115,"enrollment":775,"conditions":776,"interventions":778},"NCT02686684","Tecfidera Diffusion Tensor Imaging",[],"2016-10",115,[777],"Multiple Sclerosis, Dimethyl Fumarate, Diffusion Tensor Imaging Magnetic Resonance Imaging",[779],"Dimethyl fumarate",{"intervention":94,"totalTrials":24,"cells":781},{"EARLY_PHASE1":782,"PHASE1":784,"PHASE2":786,"PHASE3":788,"PHASE4":790,"NA":796},{"trials":783,"activeCount":11},[],{"trials":785,"activeCount":11},[],{"trials":787,"activeCount":11},[],{"trials":789,"activeCount":11},[],{"trials":791,"activeCount":11},[792],{"nctId":83,"briefTitle":84,"status":85,"phases":793,"primaryCompletion":87,"completion":88,"start":89,"enrollment":90,"conditions":794,"interventions":795},[39],[92],[94,70],{"trials":797,"activeCount":11},[798],{"nctId":799,"briefTitle":800,"status":58,"phases":801,"primaryCompletion":802,"completion":803,"start":804,"enrollment":805,"conditions":806,"interventions":808},"NCT00467987","Effect of Androgel on Atherogenesis in Type 2 Diabetic Males With Hypogonadotrophic Hypogonadism",[40],"2018-03-01","2018-10-11","2007-06-01",47,[807],"Type 2 Diabetic Male With Hypogonadotrophic Hypogonadism",[94],{"intervention":768,"totalTrials":8,"cells":810},{"EARLY_PHASE1":811,"PHASE1":813,"PHASE2":815,"PHASE3":817,"PHASE4":819,"NA":821},{"trials":812,"activeCount":11},[],{"trials":814,"activeCount":11},[],{"trials":816,"activeCount":11},[],{"trials":818,"activeCount":11},[],{"trials":820,"activeCount":11},[],{"trials":822,"activeCount":11},[823],{"nctId":760,"briefTitle":761,"status":85,"phases":824,"primaryCompletion":763,"completion":763,"start":764,"enrollment":765,"conditions":825,"interventions":826},[],[767,768],[745,768],{"intervention":828,"totalTrials":8,"cells":829},"Resveratrol 40 mg oral three times a day",{"EARLY_PHASE1":830,"PHASE1":832,"PHASE2":834,"PHASE3":836,"PHASE4":838,"NA":840},{"trials":831,"activeCount":11},[],{"trials":833,"activeCount":11},[],{"trials":835,"activeCount":11},[],{"trials":837,"activeCount":11},[],{"trials":839,"activeCount":11},[],{"trials":841,"activeCount":11},[842],{"nctId":843,"briefTitle":844,"status":58,"phases":845,"primaryCompletion":846,"completion":846,"start":847,"enrollment":62,"conditions":848,"interventions":849},"NCT01158417","Resveratrol in Type2 Diabetes and Obesity",[40],"2012-07-08","2008-12",[21,26,28],[828,850],"Resveratrol 500 mg oral once daily.",{"intervention":850,"totalTrials":8,"cells":852},{"EARLY_PHASE1":853,"PHASE1":855,"PHASE2":857,"PHASE3":859,"PHASE4":861,"NA":863},{"trials":854,"activeCount":11},[],{"trials":856,"activeCount":11},[],{"trials":858,"activeCount":11},[],{"trials":860,"activeCount":11},[],{"trials":862,"activeCount":11},[],{"trials":864,"activeCount":11},[865],{"nctId":843,"briefTitle":844,"status":58,"phases":866,"primaryCompletion":846,"completion":846,"start":847,"enrollment":62,"conditions":867,"interventions":868},[40],[21,26,28],[828,850],{"intervention":870,"totalTrials":8,"cells":871},"Victoza",{"EARLY_PHASE1":872,"PHASE1":874,"PHASE2":876,"PHASE3":878,"PHASE4":880,"NA":882},{"trials":873,"activeCount":11},[],{"trials":875,"activeCount":11},[],{"trials":877,"activeCount":11},[],{"trials":879,"activeCount":11},[],{"trials":881,"activeCount":11},[],{"trials":883,"activeCount":11},[884],{"nctId":885,"briefTitle":886,"status":85,"phases":887,"primaryCompletion":888,"completion":656,"start":889,"enrollment":890,"conditions":891,"interventions":892},"NCT02777073","Effects of Single Doses of Liraglutide and Dapagliflozin on Ketogenesis in Type 1 Diabetes",[40],"2016-12-01","2016-03-01",43,[18],[870,893],"Dapagliflozin 10mg Tab",{"intervention":893,"totalTrials":8,"cells":895},{"EARLY_PHASE1":896,"PHASE1":898,"PHASE2":900,"PHASE3":902,"PHASE4":904,"NA":906},{"trials":897,"activeCount":11},[],{"trials":899,"activeCount":11},[],{"trials":901,"activeCount":11},[],{"trials":903,"activeCount":11},[],{"trials":905,"activeCount":11},[],{"trials":907,"activeCount":11},[908],{"nctId":885,"briefTitle":886,"status":85,"phases":909,"primaryCompletion":888,"completion":656,"start":889,"enrollment":890,"conditions":910,"interventions":911},[40],[18],[870,893],{"intervention":682,"totalTrials":8,"cells":913},{"EARLY_PHASE1":914,"PHASE1":916,"PHASE2":918,"PHASE3":920,"PHASE4":922,"NA":924},{"trials":915,"activeCount":11},[],{"trials":917,"activeCount":11},[],{"trials":919,"activeCount":11},[],{"trials":921,"activeCount":11},[],{"trials":923,"activeCount":11},[],{"trials":925,"activeCount":11},[926],{"nctId":674,"briefTitle":675,"status":85,"phases":927,"primaryCompletion":677,"completion":678,"start":404,"enrollment":642,"conditions":928,"interventions":929},[40],[28],[681,682,505],{"intervention":931,"totalTrials":8,"cells":932},"Ocrelizumab",{"EARLY_PHASE1":933,"PHASE1":935,"PHASE2":937,"PHASE3":939,"PHASE4":941,"NA":943},{"trials":934,"activeCount":11},[],{"trials":936,"activeCount":11},[],{"trials":938,"activeCount":11},[],{"trials":940,"activeCount":11},[],{"trials":942,"activeCount":11},[],{"trials":944,"activeCount":11},[945],{"nctId":946,"briefTitle":947,"status":85,"phases":948,"primaryCompletion":949,"completion":949,"start":950,"enrollment":642,"conditions":951,"interventions":952},"NCT03025269","Ocrelizumab Effects on Physiological and Cognitive Changes in Multiple Sclerosis",[],"2022-01-08","2017-11-15",[15],[931],{"intervention":954,"totalTrials":8,"cells":955},"Vytorin",{"EARLY_PHASE1":956,"PHASE1":958,"PHASE2":960,"PHASE3":962,"PHASE4":964,"NA":966},{"trials":957,"activeCount":11},[],{"trials":959,"activeCount":11},[],{"trials":961,"activeCount":11},[],{"trials":963,"activeCount":11},[],{"trials":965,"activeCount":11},[],{"trials":967,"activeCount":11},[968],{"nctId":969,"briefTitle":970,"status":85,"phases":971,"primaryCompletion":972,"completion":973,"start":974,"enrollment":975,"conditions":976,"interventions":977},"NCT01420328","To Study the Effect of Vytorin on Intracellular Lipid and Inflammation in Obese Subjects",[40],"2015-07-01","2016-07-01","2011-05-01",20,[340],[954],{"intervention":721,"totalTrials":8,"cells":979},{"EARLY_PHASE1":980,"PHASE1":982,"PHASE2":984,"PHASE3":986,"PHASE4":988,"NA":990},{"trials":981,"activeCount":11},[],{"trials":983,"activeCount":11},[],{"trials":985,"activeCount":11},[],{"trials":987,"activeCount":11},[],{"trials":989,"activeCount":11},[],{"trials":991,"activeCount":11},[992],{"nctId":711,"briefTitle":712,"status":85,"phases":993,"primaryCompletion":714,"completion":715,"start":716,"enrollment":717,"conditions":994,"interventions":995},[40],[719],[721,479],{"intervention":997,"totalTrials":8,"cells":998},"sitagliptin",{"EARLY_PHASE1":999,"PHASE1":1001,"PHASE2":1003,"PHASE3":1005,"PHASE4":1007,"NA":1009},{"trials":1000,"activeCount":11},[],{"trials":1002,"activeCount":11},[],{"trials":1004,"activeCount":11},[],{"trials":1006,"activeCount":11},[],{"trials":1008,"activeCount":11},[],{"trials":1010,"activeCount":11},[1011],{"nctId":1012,"briefTitle":1013,"status":498,"phases":1014,"primaryCompletion":677,"completion":677,"start":1015,"enrollment":11,"conditions":1016,"interventions":1018},"NCT01741103","Sitagliptin in Type I Diabetic Patients",[40],"2011-06",[1017],"Diabetes Type I",[997],{"intervention":1020,"totalTrials":8,"cells":1021},"Copaxone",{"EARLY_PHASE1":1022,"PHASE1":1024,"PHASE2":1026,"PHASE3":1028,"PHASE4":1030,"NA":1032},{"trials":1023,"activeCount":11},[],{"trials":1025,"activeCount":11},[],{"trials":1027,"activeCount":11},[],{"trials":1029,"activeCount":11},[],{"trials":1031,"activeCount":11},[],{"trials":1033,"activeCount":11},[1034],{"nctId":1035,"briefTitle":1036,"status":85,"phases":1037,"primaryCompletion":1038,"completion":1039,"start":1040,"enrollment":1041,"conditions":1042,"interventions":1043},"NCT00937157","Comparison of 1.5T vs. 3T Protocols After Treatment With Glatiramer Acetate (GA)",[40],"2010-07","2011-04","2007-09",12,[15],[1020],{"intervention":1045,"totalTrials":8,"cells":1046},"Tysabri",{"EARLY_PHASE1":1047,"PHASE1":1049,"PHASE2":1051,"PHASE3":1053,"PHASE4":1055,"NA":1057},{"trials":1048,"activeCount":11},[],{"trials":1050,"activeCount":11},[],{"trials":1052,"activeCount":11},[],{"trials":1054,"activeCount":11},[],{"trials":1056,"activeCount":11},[],{"trials":1058,"activeCount":11},[1059],{"nctId":1060,"briefTitle":1061,"status":85,"phases":1062,"primaryCompletion":502,"completion":1063,"start":1064,"enrollment":1065,"conditions":1066,"interventions":1067},"NCT00937677","Effect of Tysabri in Patients With Relapsing-Remitting Multiple Sclerosis: A Follow-up Magnetization Transfer Imaging (MTI) Study",[],"2010-11","2007-11",85,[15],[1045],{"intervention":1069,"totalTrials":8,"cells":1070},"Januvia (Sitagliptin) 100 mg",{"EARLY_PHASE1":1071,"PHASE1":1073,"PHASE2":1075,"PHASE3":1077,"PHASE4":1079,"NA":1081},{"trials":1072,"activeCount":11},[],{"trials":1074,"activeCount":11},[],{"trials":1076,"activeCount":11},[],{"trials":1078,"activeCount":11},[],{"trials":1080,"activeCount":11},[],{"trials":1082,"activeCount":11},[1083],{"nctId":1084,"briefTitle":1085,"status":85,"phases":1086,"primaryCompletion":678,"completion":678,"start":1087,"enrollment":1088,"conditions":1089,"interventions":1090},"NCT00659711","The Effect of Januvia (Sitagliptin) on Oxidative Stress in Obese Type 2 Diabetic Subjects",[40],"2008-03",22,[21],[1069]]